性欲减退与使用HMG-CoA还原酶抑制剂有关吗？
Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
作者信息
de Graaf L, Brouwers A H P M, Diemont W L
机构信息
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH 's-Hertogenbosch, The Netherlands.
出版信息
Br J Clin Pharmacol. 2004 Sep;58(3):326-8. doi: 10.1111/j.1365-2125.2004.02128.x.
Abstract
AIMS AND METHODS
To describe patients with decreased libido during use of a HMG-CoA-reductase-inhibitor, and to discuss causality and pharmacological hypotheses for this association by analysis of the adverse drug reactions (ADR) database of the Netherlands Pharmacovigilance Centre Lareb.
RESULTS
Eight patients were identified as having decreased libido during use of statins. In two of these cases testosterone levels were determined and appeared to be decreased.
CONCLUSION
Decreased libido is a probable adverse drug reaction of HMG-CoA-reductase-inhibitors and is reversible. The ADR may be caused by low serum testosterone levels, mainly due to intracellular cholesterol depletion.
摘要
目的与方法
描述使用HMG-CoA还原酶抑制剂期间出现性欲减退的患者，并通过分析荷兰药物警戒中心Lareb的药物不良反应（ADR）数据库，探讨这种关联的因果关系和药理学假设。
结果
8名患者被确定在使用他汀类药物期间出现性欲减退。其中2例测定了睾酮水平，结果显示降低。
结论
性欲减退可能是HMG-CoA还原酶抑制剂的药物不良反应，且是可逆的。该不良反应可能由血清睾酮水平降低引起，主要是由于细胞内胆固醇耗竭。
相似文献
1
Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
Br J Clin Pharmacol. 2004 Sep;58(3):326-8. doi: 10.1111/j.1365-2125.2004.02128.x.
2
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
Neth J Med. 2006 Oct;64(9):334-8.
3
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
S Afr Med J. 2002 Aug;92(8):596-7.
4
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Acta Derm Venereol. 2004;84(3):229-30. doi: 10.1080/00015550310006851.
5
[Not just decreased LDL level is decisive. Which statin for patients at risk for coronary disease?].
MMW Fortschr Med. 2004 Jun 10;146(24):1-3.
6
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Rev Esp Cardiol. 1995 Jan;48(1):59-65.
7
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Int J Clin Pharmacol Ther. 1995 Jul;33(7):420-6.
8
Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Drug Saf. 2006;29(12):1163-72. doi: 10.2165/00002018-200629120-00007.
9
[High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit. 2003;32(6):516-7. doi: 10.1002/pauz.200390134.
10
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Biomed Pharmacother. 1996;50(6-7):269-74. doi: 10.1016/0753-3322(96)84824-4.
引用本文的文献
1
Lipid-Lowering Therapy Associated Erectile Dysfunction and Testicular Pain: A Rare Case Report.
Hosp Pharm. 2024 Dec 17:00185787241303994. doi: 10.1177/00185787241303994.
2
Association between atorvastatin and erectile dysfunction: a comprehensive analysis incorporating real-world pharmacovigilance and Mendelian randomization.
Front Pharmacol. 2024 Apr 29;15:1382924. doi: 10.3389/fphar.2024.1382924. eCollection 2024.
3
Association of high LDL concentrations with erectile dysfunction from a Mendelian randomization study.
Sci Rep. 2023 Dec 14;13(1):22252. doi: 10.1038/s41598-023-49771-1.
4
Association between genetically proxied HMGCR inhibition and male reproductive health: A Mendelian randomization study.
Medicine (Baltimore). 2023 Sep 29;102(39):e34690. doi: 10.1097/MD.0000000000034690.
5
The Effect of Statins on Male Reproductive Parameters: A Mechanism Involving Dysregulation of Gonadal Hormone Receptors and TRPV1.
Int J Mol Sci. 2023 May 25;24(11):9221. doi: 10.3390/ijms24119221.
6
Statins and Male Fertility: Is There a Cause for Concern?
Toxics. 2022 Oct 20;10(10):627. doi: 10.3390/toxics10100627.
7
Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database.
Drug Saf. 2022 Jun;45(6):639-650. doi: 10.1007/s40264-022-01174-3. Epub 2022 Apr 7.
8
The effect of atorvastatin on penile intracavernosal pressure and cavernosal morphology in normocholesterolemic rats.
Turk J Urol. 2018 Aug 31;45(2):91-96. doi: 10.5152/tud.2018.98048. Print 2019 Mar.
9
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
Arch Med Sci. 2015 Mar 16;11(1):1-23. doi: 10.5114/aoms.2015.49807. Epub 2015 Mar 14.
10
Statins and male sexual health: a retrospective cohort analysis.
J Sex Med. 2015 Jan;12(1):158-67. doi: 10.1111/jsm.12745. Epub 2014 Nov 25.
本文引用的文献
1
Do lipid-lowering drugs cause erectile dysfunction? A systematic review.
Fam Pract. 2002 Feb;19(1):95-8. doi: 10.1093/fampra/19.1.95.
2
The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
Eur J Clin Pharmacol. 2001 Apr;57(1):89-91. doi: 10.1007/s002280100265.
3
Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients.
J Endocrinol Invest. 1998 May;21(5):310-7. doi: 10.1007/BF03350334.
4
Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment.
Horm Metab Res. 1996 Apr;28(4):193-8. doi: 10.1055/s-2007-979159.
5
Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.
J Clin Endocrinol Metab. 1995 Mar;80(3):836-40. doi: 10.1210/jcem.80.3.7883839.
6
The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity.
J Steroid Biochem Mol Biol. 1991 Apr;38(4):465-8. doi: 10.1016/0960-0760(91)90333-z.
7
Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.
Br J Clin Pharmacol. 1991 Oct;32(4):417-22. doi: 10.1111/j.1365-2125.1991.tb03924.x.
Zotero 插件